PSY42 Understanding What Patients Value And Their Willingness-To-Pay (Wtp) For Hemophilia TherapiesA Discrete Choice Experiment  by Chaugule, S et al.
A230  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
below the 70th percentile and 1 (poor adherence) if above the 70th percentile. ABR 
was also dichotomized into no bleeds (0 ABR), the true goal of prophylaxis, versus 
1 or more bleeds (1+ ABR). Results: Reported ABR ranged from 0 to 54 (median 
1). There was not a significant relationship between VERITAS-Pro score and ABR. 
There was a significantly greater percentage of patients experiencing one or more 
bleeds in the VERITAS-Pro poor adherence group (86%) than in the VERITAS-Pro good 
adherence group (62%). ConClusions: VERITAS-Pro scores reflecting adherence 
are significant predictors of ABR; individuals with poor adherence on the VERITAS-
Pro are more likely to have at least 1 bleed per year versus those with good adher-
ence. However, the high percentage of patients experiencing one or more bleeds in 
both groups indicates that factors other than adherence may impact annualized 
bleed rates.
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objeCtives: For people with hemophilia A, factor VIII (FVIII) prophylaxis is 
burdensome, potentially leading to poor compliance. Treatment adherence and 
outcomes may be improved with drugs requiring less frequent infusions. In the 
absence of head-to-head direct comparative evidence from clinical trials, this 
analysis indirectly compared the prophylactic efficacy of recombinant FVIII Fc 
fusion protein (rFVIIIFc) with the published results of current rFVIII products and 
simulated effects of potential differences in real-world compliance between regi-
mens. Methods: rFVIIIFc and rFVIII were indirectly compared using data from 
previously treated subjects in the A-LONG phase 3 study (rFVIIIFc; individualized 
arm) and published clinical studies of routine prophylaxis (rFVIII; identified by lit-
erature search). Efficacy was compared using reported differences in mean annual-
ized bleed rates (ABRs) for individual and pooled results using meta-analysis with 
random effects. Unreported standard deviations of ABR were estimated assuming 
a Poisson distribution and adjusted for over-dispersion. A model was developed to 
assess the effect of compliance changes on ABR. Results: This analysis included 
published results from the A-LONG study (severe hemophilia; rFVIIIFc; Mahlangu 
2013) and 4 studies of rFVIII (moderate/severe hemophilia; Advate®: Tarantino 
2004, Shapiro 2003, and Valentino 2012; Xyntha®: Recht 2009). Infusion frequencies 
were 1.4-2.4 (median 2.0) times/week for rFVIIIFc and 2.3-4 times/week for rFVIII. 
Mean ABR for rFVIIIFc was 2.9; the pooled mean ABR estimate for rFVIII was 4.8 
(I2 = 44.2%, Δ ABR= 1.8; P= 0.003). Simulations showed that statistically significant 
improvements in mean ABR would result from improving compliance with rFVIIIFc 
by ≥ 6-12 percentage points. CONCLUSIONSResults of this unadjusted indirect 
comparison of clinical studies suggest that routine prophylaxis with rFVIIIFc may 
result in a lower mean ABR than that of other rFVIII products examined. Moreover, 
potential improvements in compliance associated with less burdensome dosing 
requirements, as suggested by studies in other chronic diseases, may result in 
better effectiveness with rFVIIIFc.
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objeCtives: Hemophilia B prophylaxis with factor IX (FIX) requires frequent infu-
sions, potentially leading to poor compliance and reduced therapeutic effectiveness. 
In the absence of head-to-head direct comparative evidence from clinical trials, this 
analysis indirectly compared the prophylactic efficacy of recombinant FIX Fc fusion 
protein (rFIXFc) and other rFIX products, which require more frequent infusions. 
Additionally, we simulated the effects of potential differences in real-world com-
pliance between regimens. Methods: rFIXFc and rFIX were indirectly compared 
using data from clinical trials of previously treated subjects administered rFIXFc 
(B-LONG phase 3 study, weekly prophylaxis arm) or rFIX (published clinical stud-
ies of routine prophylaxis identified by literature search). Efficacy was compared 
using reported differences in mean annualized bleed rates (ABRs) for individual 
and pooled results using meta-analysis with random effects. Unreported standard 
deviations of ABR were estimated assuming a Poisson distribution and adjusted for 
over-dispersion. A model simulating the effect of improved compliance on ABR was 
developed. Results: This analysis included results from the published B-LONG 
study (severe hemophilia; rFIXFc; Powell 2013) and 4 published studies of rFIX (mod-
erate/severe hemophilia; BeneFIX®: Roth 2001, Lambert 2007, and Korth-Bradley 
2011; Rixubis®: Windyga 2012). Infusion frequencies were once weekly for rFIXFc, 
and 1 to > 3 times/week (Roth 2001, Lambert 2007) or 1-2 times/week (Korth-Bradley 
2011, Windyga 2012) for rFIX. Mean ABR for rFIXFc was 3.07; the pooled mean ABR 
estimate for rFIX was 3.84 based on these clinical studies (I2= 57.5%, Δ ABR= 0.77; 
P= 0.23). Simulations showed that statistically significant improvements in mean 
ABR would result from improving compliance with rFIXFc by ≥ 9-14 percentage 
points. ConClusions: Based on simulations of potential differences in real-world 
compliance, less burdensome dosing with rFIXFc may lead to improved real-world 
effectiveness, consistent with findings in other chronic diseases.
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objeCtives: The purpose of this analysis is to examine hospital-based utilization 
in Wegener’s granulomatosis (WG), a form of autoimmune disease characterized 
by necrotizing granulomas and vasculitis affecting approximately 3 out of every 
100,000 people in the US. Methods: A retrospective cross-sectional analysis exam-
ined inpatient (N= 7,202) and outpatient visits (N= 24,971) in the MedAssets health 
system data from 2009 to 2013. In addition to patient and hospital characteristics, 
the Charlson comorbidity index and its individual comorbidities were evaluated. 
Analysis of prevalent procedures and their comparative effects on utilization were 
explored. Measures of utilization included number of visits and length of stay (LOS). 
Negative-binomial multivariate regression was used to identify significant LOS driv-
ers. Results: Hospital utilization was primarily for outpatient services (77.6%) with 
a mean of 2.5 outpatient visits per patient. The primary diagnosis was WG for 58.6% 
of outpatients and16.6% of inpatients. Other common inpatient diagnoses included 
pneumonia (5.2%), septicemia (3.5%), and acute renal failure (3.4%). The sample 
included more females (54.6%) than males (45.3%) and 56.8% was between 40 and 
69 years old. The mean Charlson score was 2.11 with renal disease (37.4%), chronic 
pulmonary disease (27.2%), diabetes (18.9%), congestive heart failure (11.1%), and 
rheumatic disease (10%) as the most prevalent comorbidities. The most common 
inpatient procedures were hemodialysis (26.3%), packed cell transfusions (18.0%), 
closed bronchial biopsy (8.1%), and closed renal biopsy (6.5%). Average LOS was 
8.4 days. The most significant drivers associated with longer LOS included bron-
chial (IRR= 1.72, p< .0001) and renal (IRR= 1.48, p< .0001) biopsy procedures, packed 
cell transfusions (IRR= 1.41 ,p< .0001), and therapeutic plasmapheresis (IRR= 1.34, 
p< .0001). ConClusions: Although a rare disease WG patients consume signifi-
cant amounts of health care resources in the hospital setting. Primary utilization 
occurs in the outpatient setting, however, when hospitalized LOS is often lengthy. 
Further research is required to understand the effect of interventions/treatments 
on mitigating progress of this disease.
SYStemIc dISorderS/condItIonS – Patient-reported outcomes & Patient 
Preference Studies
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objeCtives: Fibromyalgia is a disorder characterized by widespread chronic mus-
culoskeletal pain. This study aims to understand the treatment patterns associated 
with currently available and commonly used medications in the management of 
fibromyalgia. Methods: This retrospective study used the MarketScan claim data-
base to identify patients who had a first fibromyalgia diagnosis code (ICD-9-CM: 
729.1) in 2009-2011 with a repeat diagnosis within a year; were at least 18 years old; 
and had continuous enrollment for ≥ 12 months before and after the date of first 
diagnosis, i.e. the index date. The pain treatments assessed were: anticonvulsants 
(pregabalin, gabapentin), antidepressants (amitriptyline, cyclobenzaprine, venlafax-
ine, duloxetine, milnacipran), and opioid (tramadol). Adherence was evaluated using 
percent of days covered (PDC) and categorized into low (< 50%), medium (50%-80%), 
and high (≥ 80%). The 1-year discontinuation (defined as the first drug supply gap 
≥ 90 days) rate was estimated using Kaplan-Meier curve. Results: A total of 240,144 
patients met the inclusion criteria; 68% were female and the study sample mean 
(SD) age was 48 (13.8) years. Only 31% (N= 74,738) of the patients initiated a treatment 
of interest within a year after the index date. The 3 most frequently dispensed ones 
were cyclobenaprine (27.4%), tramadol (17.9%), and gabapentin (16.3%). Duloxetine, 
pregabalin, and milnacipran accounted for 13.6%, 8.9%, and 3.8% of treated patients 
respectively. Adherence was suboptimal for all of these treatments: mean PDCs (% 
with high adherence) were 59% (39%), 47% (24%), 44% (22%), 43% (21%), 27% (9%), 
and 20% (5%) for duloxetine, pregabalin, gabapentin, milnacipran, tramadol, and 
cyclobenaprine, respectively; and the corresponding 1-year discontinuation rates 
were 52%, 65%, 67%, 72%, 80%, and 90%, respectively. ConClusions: The major-
ity of patients diagnosed with fibromyalgia were not treated with the assessed 
therapies in this study cohort. Adherence and persistence with the current pain 
medications were sub-optimal.
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objeCtives: Few studies exist to support the hypothesis that nonadherence to 
prophylactic treatment of hemophilia leads to increased bleeding. The VERITAS-Pro, 
a validated measure of adherence to prophylaxis, allows objective measurement of 
the relationship between adherence and patient outcomes. The study objective was 
to correlate VERITAS-Pro scores and annual bleed rate (ABR), defined as the number 
of bleeds a patient has in a given year. Methods: The study sample was comprised 
of patients utilizing prophylaxis treatment who completed the VERITAS-Pro for the 
validation study published by Duncan et al in Haemophilia in 2007 (n= 66). ABR was 
extrapolated from patient infusion logs and, for those patients with incomplete or 
missing logs, from electronic medical records. Pearson and Spearman correlational 
analyses were run between VERITAS-Pro scores and ABR. A cutoff analysis was 
done in which the 70th percentile was chosen as a clinically useful cutoff score 
and VERITAS-Pro scores were dichotomized and coded as 0 (good adherence) if 
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based on the same clinical studies and corresponded to improvement in respira-
tory symptoms (as measured by the CFQ-R). In one case, the improvement in res-
piratory symptoms was considered as primary endpoint (aztreonam lysine – one 
study). ConClusions: There are few PRO labeling claims in products approved for 
CF in Europe and the United States. Discrepancies exist in the CF guidance issued by 
the FDA and the EMA, where EMA is more favorable to PRO endpoints.
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objeCtives: Chronic low back pain is a persistent disabling condition that impairs 
the individual’s functional status and poses as an economic burden to the society. 
The objectives of this study were to examine the pain-related disability, self-effi-
cacy and coping strategies of adult patients with chronic low back pain and their 
relationships, the differences in pain-related disability, self-efficacy and coping 
strategies used among socio-demographic and clinical characteristic subgroups, 
and to identify the predictors of pain-related disability. Methods: A descriptive, 
correlational questionnaire survey design was used. A convenience sample of 65 
patients aged 21 years or above with a diagnosis of chronic low back pain was 
recruited from a public hospital in Singapore from September 2012 to January 2013. 
Roland-Morris Disability Questionnaire, Chronic Low Back Pain Self-Efficacy Scale, 
and Coping Strategies Questionnaire-24 were used to collect data. Descriptive statis-
tics, independent sample t-test, analysis of variance, and Peanson Product-moment 
Correlation Coefficent were used to analyse the data. Results: The participants 
had moderate levels of pain-related disability and self-efficacy, and used both active 
and passive coping strategies. Significant differences in pain-related disability, self-
efficacy and coping strategies used were found among subgroups of various socio-
demographics. Significant differences in pain-related disability were found within 
one subgroup of clinical variable. Pain-related disability had a significant negative 
relationship with self-efficacy and positive relationship with passive coping, while 
self-efficacy had a significant positive relationship with active coping and a nega-
tive relationship with passive coping. Self-efficacy, ethnicity and monthly income 
were predictors of pain-related disability. ConClusions: Our findings indicate 
the need to enhance patients’ self-efficacy and reduce the use of passive coping 
strategies in order to decrease pain-related disability. Future intervention studies 
improving patients’ self-efficacy and coping are needed to improve patients’ well-
being and quality of life.
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objeCtives: Patient-reported measures of Vaso Occlusive Crisis (VOC) outcomes 
reported in literature were identified and quality of evidence for each type of meas-
ure was assessed. Methods: PubMed, COCHRANE and CINAHL databases (1966 
through August 2012) and reference lists of identified articles were searched for any 
patient-reported measures employed to assess VOC outcomes. Identified measures 
were categorized as: measures assessing pain, and measures assessing quality of 
life (QoL) due to VOC. Studies were assessed for quality of evidence based on risk 
of bias (coded ‘1’ for randomized controlled study without any serious limitations, 
else ‘0’), consistency (coded ‘1’ for demonstrated clinical and methodological homo-
geneity, else ‘0’), directness (coded ‘1’ for use of non-surrogate endpoint, else ‘0’) 
and precision (coded ‘1’ if total number of cases across all studies of measure was 
greater than 400, else ‘0’). Overall quality of evidence was calculated by summation 
of each domain score, where ‘4’ meant ‘high,’ ‘3,’ ‘moderate,’ ‘2,’ ‘low’ and scores 
less than or equal to ‘1’ denoted ‘very low’ quality of evidence. Results: A total of 
1,620 potentially relevant studies were identified and reviewed. Of those, 63 stud-
ies passed inclusion criteria and were retained for analyses. Twenty-three unique 
patient-reported measures of VOC outcomes were identified and categorized. Fifty-
seven studies employed pain based measures and 12 studies employed QoL based 
measures. While, overall mean quality of evidence score was 2.17, mean quality of 
evidence score for pain based measures was 2.35 and for QoL based measures was 
1.42. The most commonly employed pain based measures were Visual Analog Scales 
(VAS), (28 studies), whereas, the most commonly employed QoL based measure was 
school/work attendance, (4 studies). ConClusions: A variety of patient-reported 
measures of VOC outcomes were identified and categorized. VAS, and face based 
scales had higher quality of evidence compared to measure of school/work attend-
ance.
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objeCtives: 1) To identify products indicated for the treatment of rare diseases 
approved through the centralized procedure in Europe, and (2) To list the products 
which obtained a PRO labeling claim. Methods: The search was performed on 
the European Medicines Agency (EMA) website (11/12/2013). The European public 
assessment reports (EPARs) were browsed by type (i.e., orphan medicines). Products 
refused were excluded. Then, the PROLabels database was searched for each product 
retrieved to identify any PRO claim in the corresponding label. Results: A total of 
69 orphan medicines were identified on the EMA website, representing 11 different 
objeCtives: Despite the clearly evident better clinical outcomes with prophy-
laxis compared to on-demand therapy, on average only 55% of patients diagnosed 
with severe hemophilia receive prophylactic factor replacement therapy in the US. 
Prophylaxis generally drops with age, partly due to patients becoming more inde-
pendent and less compliant as they reach adulthood and partly due to reduced 
perceived benefit. High treatment costs of prophylaxis therapy also remains a 
barrier. Further, the development of long-acting factor products offering a mod-
est improvement in convenience is likely to drive-up treatment costs. This study 
aims to understand hemophilia patient preferences and their willingness-to-pay 
for hemophilia therapies (on-demand, standard prophylaxis, longer-acting prophy-
laxis). Methods: U.S. adult patients and caregivers of children with hemophilia (n 
= 79) completed a discrete-choice survey that presented a series of trade-off ques-
tions, each including a pair of hypothetical treatment profiles, that had an assigned 
cost for attaining improvement in health states. The relative importance of treat-
ment attributes such as out-of-pocket treatment costs, dose adjustment, treatment 
related complications and clinical efficacy & dosing regimen was analyzed using 
mixed logit models. Based on the attribute estimates, patients’ WTP was deter-
mined. Results: Out-of-pocket treatment costs (P < .001), treatment complications 
(P < .001) and clinical efficacy & dosing regimen (P < .001) were perceived to be the 
most important treatment attributes. Patients were willing to pay on average $150 
per/month for improvement in each of the prophylaxis dosing regimens (i.e. 3 times 
weekly vs 2 times weekly vs. 1 time weekly vs. 1 time in two weeks). ConClusions: 
The results suggest that patients are willing to pay more for improvements in treat-
ment related complications, clinical efficacy & dosing regimen. These estimates of 
patients’ willingness-to-pay can be used to provide guidelines for resource alloca-
tion. Literature also suggests that patient preferences are likely to directly translate 
into increased treatment adherence, leading to greater treatment effectiveness.
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PSYchometrIc ProPertIeS of the adhd ratIng Scale-IV (adhd rS-IV) 
and adult adhd Self-rePort Scale (aSrS) In a PhaSe 3b clInIcal trIal 
of PatIentS WIth PhenYlketonurIa
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objeCtives: Phenylketonuria (PKU) is the most common in-born error of metabo-
lism and is associated with neuropsychiatric sequelae. Interviews among adults 
and parents of children with PKU have established that inattentiveness is an 
important psychiatric symptom. Although the Adult ADHD Self-Rating Scale (ASRS; 
self-report) and ADHD Rating Scale (ADHD RS-IV; parent-report) instruments have 
been validated for measuring symptoms of inattentiveness in persons with ADHD, 
their psychometric value for measuring PKU-related inattentiveness has not been 
established. This study investigated the psychometric properties of the ASRS and 
ADHD RS-IV inattentiveness subscales in a PKU population ≥ 8 years old. Methods: 
A post-hoc analysis was conducted in participants ≥ 8 years of age in a Phase 3b 
double blind, placebo-controlled clinical trial in PKU over a 13-week period. The 
ASRS/ADHD RS-IV reliability, construct validity, and responsiveness were meas-
ured using clinician- and adult-/parent-reported outcomes collected in this clini-
cal trial. Results: Data analysis revealed strong internal consistency reliability 
for both measures (α ≥ 0.87). In addition, the test-retest analyses resulted in ICCs 
≥ 0.87, indicating outstanding agreement between the Baseline and Week 4 (re-test 
visit) measures for both the adult- and parent-rated inattentiveness subscales. Both 
inattentiveness measures demonstrated an ability to discriminate between known 
groups (p< 0.0001) defined by the Clinical Global Impression-Severity (CGI-S) scale. 
Correlations between the ASRS/ADHD RS-IV with the CGI-S and age-appropriate 
Behavior Rating Inventory of Executive Function (BRIEF) Working Memory subscale 
were consistently moderate-to-strong (r ≥ 0.56). Similarly, results of the change score 
correlations were moderate (r ≥ 0.43) for both measures when compared to changes 
over time in the BRIEF Working Memory subscale. ConClusions: These findings 
of reliability, validity, and responsiveness of both the ASRS and the ADHD RS-IV 
inattentiveness sub-scales, in addition to content validation results, further support 
their use for the assessment of inattentive symptoms among persons with PKU ≥ 8 
years old in clinical trials.
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objeCtives: The objective of this research was to review the role of patient-reported 
outcomes (PROs) in drug approval and labeling of products authorized for the treat-
ment of cystic fibrosis (CF) in Europe and in the United States. Methods: This 
research was conducted through a systematic manual review of CF specific regula-
tory guidelines and product labelings (US and EU). The PROLabels database was used 
for the label review. FDA medical reviews and EMA assessment reports were also 
used to review the clinical studies performed for regulatory approval. Results: 
In its guideline specific to CF, the EMA recommends the use of the Cystic Fibrosis 
Questionnaire-Revised (CFQ-R) and labels it as a quality-of-life endpoint. The CFQ-R 
is a disease-specific instrument designed to measure impact on overall health, 
daily life, perceived well-being and symptoms. There is no specific FDA guidance 
on CF: the corresponding FDA guidance only covers exocrine pancreatic insuffi-
ciency drug products and recommends steatorrhea as the main endpoint. A total of 
seven different products (seven brand names, six INN) indicated for the treatment 
of cystic fibrosis were identified: five were approved by the EMA, and five by the 
FDA. Three products were common to both agencies: aztreonam lysine, ivacaftor 
and tobramycin. Two products were identified with a PRO claim in Europe and in 
the United States, i.e., aztreonam lysine and ivacaftor. In both cases, the claim was 
